Effect of Pentoxifylline in Ameliorating Myocardial Injury in Patients With Myocardial Infarction Undergoing Thrombolytic Therapy: A Pilot Randomized Clinical Trial

2017 ◽  
Vol 57 (10) ◽  
pp. 1338-1344 ◽  
Author(s):  
Hossein Namdar ◽  
Rasoul Zohori ◽  
Naser Aslanabadi ◽  
Taher Entezari-Maleki
Keyword(s):  
Myocardial Infarction ◽  
Clinical Trial ◽  
Thrombolytic Therapy ◽  
Randomized Clinical Trial ◽  
Myocardial Injury

The effects of Allopurinol on levels of cardiac troponin Following Non-ST Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial

2021 ◽  
Author(s):  
Sajad Khiali ◽  
Parvin Sarbakhsh ◽  
Sina Mashayekhi ◽  
Elham Mohamadrezapour ◽  
Samaneh Dousti ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Cardiac Troponin ◽  
Myocardial Injury ◽  
Standard Treatment ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
St Elevation Myocardial Infarction ◽  
St Elevation

Purpose: Given the potential anti-ischemic effects of allopurinol, we aimed to assess whether allopurinol administration may reduce myocardial injury following non-ST elevation myocardial infarction (NSTEMI). Methods: A randomized clinical trial (RCT) was conducted on 100 individuals with NSTEMI. The intervention group (n=50) received 600 mg oral allopurinol at the time of diagnosis of NSTEMI, followed by 300 mg every day for two next days and the standard treatment of NSTEMI, while the control group (n=50) received only the standard treatment. Serum concentrations of cardiac troponin I (cTnI) were measured at baseline, and 8, 16, 24, and 32 hours after the treatment. Results: The baseline demographic and clinical data of the patients were not statistically different between the intervention and control groups (all P > 0.05). The comparing estimated marginal mean ± standard error for cardiac troponin I (cTnI) levels revealed no significant difference between the study groups (2.93 ± .27, 2.25 ± .27; P=0.082). The linear mixed model results showed that the interaction of time and group was not statistically different (P=0.751). Moreover, there was a decreasing trend over time for cTnI in both groups (P=0.039). Conclusion: The present pilot RCT did not support the potential cardio-protective benefits of allopurinol administration on decreasing myocardial injury following NSTEMI.

Sas enterprise guide 6.1: independent groups comparison for nominal data

2020 ◽  
Vol 20 (3) ◽  
pp. 89-98
Author(s):  
N. S. Bunenkov ◽  
G. F. Bunenkova ◽  
V. V. Komok ◽  
O. A. Grinenko ◽  
A S. Nemkov
Keyword(s):  
Myocardial Infarction ◽  
Clinical Trial ◽  
Data Analysis ◽  
Randomized Clinical Trial ◽  
Postoperative Bleeding ◽  
Nominal Data ◽  
Saint Petersburg ◽  
Develop Algorithm ◽  
Chi Squared ◽  
Medical University

Objective:to develop algorithm of independent groups comparison for nominal data of prospective non-randomized clinical trial AMIRI CABG (ClinicalTrials.gov Identifier: NCT03050489) using SAS Enterprise Guide 6.1. Materials and methods.Data collection was performed according to prospective non-randomized clinical trial AMIRI CABG in Pavlov First St. Petersburg State Medical University, Saint Petersburg, Russia between 2016-2019years with 336 patients. Patients were allocated into three groups of treatment. There is database which include following information: gender, myocardial infarction, stroke and postoperative bleeding. Comparison for nominal data (gender and incidence of myocardial infarction, stroke and bleeding) were calculated with SAS Enterprise Guide6.1 software with Chi-squared test and exact Fisher test. Results.There was developed algorithm of two independent groups comparison for nominal data. Conclusion.Presented algorithm of data analysis allows to compare independent groups for nominal data.

Sign in / Sign up

Export Citation Format

Share Document